Insider buying last 90 days
No open-market insider purchases were filed for ILMN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ILMN insider filing, plotted on the chart in Gekko.Open ILMN in Gekko
NASDAQ: ILMN
Illumina (ILMN) Stock Analysis & Forecast
$239.62−5.56 (−2.3%)
Close on Sep 18, 2026. Page updated Sep 19, 9:17 pm ET.
Gekko Brief
AI summaryIllumina (ILMN) closes at $239.62, down 2.3% on the day but well above both its 50-day average of $204.06 and 200-day average of $156.06, with the shorter average above the longer one. The GekkoIndex reading of 43.2 places the stock in the Distribution zone, down 16.5 over the past five readings. Gekko Fair Value stands at $203.50, putting the current price 17.7% above that level. One-year return sits at 137.6%, with the stock trading near its 52-week high of $250.06 and well off its low of $88.00.
This week's news centers on the Q2 2026 earnings call, in which Illumina reported revenue of $1.16 billion, up 9.5% reported, with EPS of $1.31 versus a $1.23 estimate. Growth was tied to NovaSeq X placements and clinical consumables demand, with clinical consumables up 15% ex-China; the company raised full-year 2026 guidance to organic revenue growth above 5% and flagged high single-digit growth expected in 2027. The stock also touched a 52-week high of $231.82 and jumped 5.2% to $219.11 during a broader rally among diagnostics and research peers including TMO. Separately, Baird Financial Group disclosed a 14.6% reduction in its ILMN stake, now holding 182,425 shares.
Looking to the next 20 trading days, the next earnings date falls on 29 October 2026, 39 days out, placing the report outside a typical holding window. Analyst views are mixed, with 8 of 16 firms rated buy, 5 hold, and 3 sell, and a consensus target of $202.65, implying downside of 15.4% from current levels. Seasonality over five years shows an average -1.1% return across this stretch of the calendar, with gains in only 2 of those years. No insider, Congress, or unusual options activity appears in the current 90-day and 30-day windows respectively.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $239.62200-day averageGekko Fair Value $203.50
Key stats
- Market cap
- $36.25B
- P/E ratio
- 42.7
- Forward P/E
- 37.3
- EPS, TTM
- $5.74
- Revenue, TTM
- $4.49B
- Profit margin
- 18.3%
- Dividend yield
- —
- Beta
- 1.47
- Volume
- 32.50M avg 3.60M
- 1-year return
- +137.6%
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±8.1%
- 50-day average
- $204.06
- 200-day average
- $156.06
- Next earnings
- Oct 29 after close
- Shares outstanding
- 151.0M
Illumina swing-trade checklist
Illumina scores 2 supportive, 0 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive0 mixed3 headwinds
- Trendsupportive
Above 50 and 200-day
Close $239.62 is above the 50-day ($204.06) and 200-day ($156.06) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
43.2, Distribution
Reading 43.2 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
17.7% above
Price is 17.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.1% on average
From this point in the calendar, the next 20 trading days averaged −1.1% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Illumina stock chart and price history
Illumina closed at $239.62 on Sep 18, 2026, +137.6% over the past year, inside a 52-week range of $88.00 to $250.06.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +16.9%
- 3 months
- +48.0%
- 6 months
- +89.3%
- 1 year
- +137.6%
The full ILMN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ILMN in Gekko
Follow Illumina through every session
Put ILMN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ILMN in GekkoFree for 7 days. No credit card required.
About Illumina
Illumina builds tools that read and interpret DNA, centering on sequencing and array technology. Its systems help laboratories and clinics turn genetic material into usable insight, supporting work in areas such as life sciences research, cancer diagnostics, reproductive health, and agriculture, along with newer areas of genomic study. The company is particularly associated with the instruments and related supplies that make this kind of large-scale genetic analysis possible.
Revenue comes from selling sequencing and genotyping instruments alongside the consumables they require, plus related services such as equipment servicing, licensing and development partnerships, and cancer screening tests. Customers include research institutions, universities, government and hospital laboratories, drug and biotech developers, diagnostic companies, and firms in consumer genomics. Illumina reaches these customers both by selling to them directly, across North America, Europe, Latin America and the Asia-Pacific, and through distributor partners who cover additional regions including the Middle East and Africa.
The company was founded in 1998 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker ILMN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- illumina.com
Illumina GekkoIndex: the smart money zone
Illumina’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 43.2, in the Distribution zone, down 16.5 points over five sessions.
43.2Distribution
Down 16.5 points over five sessions, from the Neutral zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 52 | −1.4% | −4.0% | ||
| Accumulation | 166 | +0.5% | −1.4% | ||
| Neutral | 396 | +1.0% | +4.3% | ||
| Distribution (current zone) | 47 | −1.3% | +2.1% | ||
| Selling | 1 | Too few readings yet | |||
Average ILMN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.3% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the ILMN price, zone by zone.Track ILMN in Gekko
Is Illumina stock overvalued? Gekko Fair Value
Illumina trades 17.7% above Gekko Fair Value of $203.50, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Illumina shares are worth, recalculated every trading day.
$203.50
Gekko Fair Value, Sep 19, 2026
17.7% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ILMN in Gekko
Illumina insider and Congress trading
No open-market insider purchases were filed for Illumina, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ILMN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ILMN, plotted on the chart in Gekko.Open ILMN in Gekko
Buybacks
Illumina has been buying back its own shares.
- Latest authorization
- $1.50B, Apr 30, 2026
- Bought back, quarter ended Jun 28, 2026
- $242.0M
- As a share of market cap
- 0.67%
- Trailing four quarters
- $656.0M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ILMN.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Illumina earnings: next date and track record
Illumina reports on Oct 29, 2026, after the close (39 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected after the close, 39 days away
- EPS estimate
- $1.36
- Revenue estimate
- $1.15B
7 of 8reports beat the EPS estimate
±10.7%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Illumina reported a strong Q2 2026 with revenue of $1.16 billion (up 9.5% reported, 6.5% organic ex-China) and EPS of $1.31 (up 10% YoY). Rest-of-world organic revenue grew 8.1% and sequencing consumables were $775 million (up 5% YoY). Clinical markets (≈65% of sequencing consumables) were the primary growth driver, with clinical consumables up 15% ex-China and the U.S.-Canada region growing above 20%. More than 95 NovaSeq X placements in the quarter expanded installed base and are expected to support continued consumables pull-through. Management reported margins and EPS above guidance despite higher-than-expected memory and freight costs, and said they have secured additional inventory to de-risk supply. The company raised its 2026 guidance for revenue growth and profitability, now expecting mid-teens growth in clinical markets for the year and reiterating a high single-digit growth target for 2027. Management highlighted multi-omics initiatives (StrataMap, TruPath, BioInsight/Billion Cell Atlas) as strategic growth drivers and said many multi-omics products show up in consumables or services. Seasonality remains relevant (Q3 typically lower than Q4), and Q4 has an extra week that could contribute roughly half a percentage point to revenue. Management emphasized operational cost actions to drive margin expansion (step to ~24% operating margin expected in Q3 from mid-Q2 levels). Overall tone from management was confident and constructive, while analysts focused on phasing, placements sustainability, memory cost trajectory, regional variability, and the research market.
- Guidance
- Raised 2026 guidance for revenue growth and profitability. Now expect mid-teens clinical consumables growth for 2026 (ex-China). Company continues to target high single-digit revenue growth for 2027. Expectation of operating margin stepping up into ~24% in Q3 (roughly +100 bps vs Q2 ex-deferred comp). Q4 includes one extra week that could add ~0.5 percentage points to revenue run-rate.
- Risks flagged
- Higher memory and freight costs and component allocation risk; regional near-term weakness in EMEA, Middle East and Latin America; ongoing softness in the research/applied market and funding variability; mid-throughput instruments are more sensitive to macro conditions; supply chain and inventory constraints; geopolitical/regulatory exposure (e.g., China unreliable entity list) that affects reported organic growth.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $1.31 est $1.23 | $1.16B est $1.13B | +5.3% |
| Apr 30, 2026 | $1.15 est $1.07 | $1.09B est $1.07B | +12.8% |
| Feb 5, 2026 | $1.35 est $1.22 | $1.16B est $1.12B | −10.8% |
| Oct 30, 2025 | $1.34 est $1.17 | $1.08B est $1.07B | +30.0% |
| Jul 31, 2025 | $1.19 est $1.02 | $1.06B est $1.06B | −11.3% |
| May 8, 2025 | $0.97 est $0.94 | $1.04B est $1.03B | −0.8% |
| Feb 6, 2025 | $0.86 est $0.92 | $1.10B est $1.07B | −10.9% |
| Nov 4, 2024 | $1.14 est $0.88 | $1.08B est $1.08B | +3.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Illumina stock forecast and analyst price targets
Analysts’ average 12-month price target for Illumina is $202.65, −15.4% from the last close, from 16 firms rating the stock in the last 90 days.
$202.65consensus 12-month target, −15.4% from the last close
Now $239.62Avg $202.65
Low $113High $260
Each firm’s latest rating in the last 90 days: 16 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 15 | Stifel Nicolaus | $225 | −6.1% |
| Sep 11 | Canaccord Genuity | — | — |
| Sep 9 | Bernstein | $215 | −10.3% |
| Sep 9 | UBS | $260 | +8.5% |
| Aug 5 | Freedom Capital Markets | $185 | −22.8% |
+2.1%average 20-day move after past Distribution readings
−1.1%average move over the next 20 trading days in the last 5 years
±4.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Illumina seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Illumina averaged −1.1% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −6.6% | 0 of 5 |
| Next 10 trading days | −3.6% | 1 of 5 |
| Next 15 trading days | −1.7% | 2 of 5 |
| Next 20 trading days | −1.1% | 2 of 5 |
| Next 30 trading days | +4.2% | 3 of 5 |
For scale, ILMN’s typical 20-trading-day move in either direction is about 8.1%.
Illumina market cap and key statistics
Illumina’s market cap is $36.25B, with a P/E ratio of 42.7 and revenue of $4.49B over the last twelve months.
Valuation
- Market cap
- $36.25B
- P/E ratio
- 42.7
- Forward P/E
- 37.3
- EPS, TTM
- $5.74
- Gekko Fair Value
- $203.50
Trading
- Volume
- 32.50M
- Avg volume, 20 days
- 3.60M
- 52-week high
- $250.06
- 52-week low
- $88.00
- Shares outstanding
- 151.0M
Financials
- Revenue, TTM
- $4.49B
- Profit margin
- 18.3%
- Return on equity
- 32.3%
- Quarterly earnings growth, YoY
- −9.4%
Risk and income
- Beta
- 1.47
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±8.1%
Illumina stock news this week
Coverage of Illumina this week reads positive: 3 positive, 0 neutral and 0 negative headlines.
- Illumina Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga, Sep 18
- Illumina stock reaches 52-week high at 231.82 USDInvesting.com, Sep 16
- Illumina Jumps 5.2% Amid Sector-Wide RallyAlphaStreet, Sep 16
- Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research, Sep 11
- Baird Financial Group Inc. Decreases Position in Illumina, Inc. $ILMNDefense World, Sep 11
Illumina peers
Illumina’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
A peer links to its own page where one exists.
Illumina stock FAQ
What is Illumina’s market cap?
Illumina’s market cap is $36.25B at the Sep 18, 2026 close of $239.62, with 151.0M shares outstanding. The shares trade on a P/E ratio of 42.7.
What is the Illumina stock forecast?
The consensus analyst 12-month price target for Illumina is $202.65, −15.4% from the last close. Of the 16 firms that rated the stock in the last 90 days, 8 rate it a buy, 5 a hold and 3 a sell. Gekko doesn’t publish price predictions of its own.
Is Illumina stock overvalued or undervalued?
On Gekko’s estimate Illumina is overvalued: the Sep 18, 2026 close of $239.62 is 17.7% above Gekko Fair Value of $203.50. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Illumina report earnings next?
Illumina is expected to report on Oct 29, 2026, after the market closes (39 days away). Analysts expect earnings of $1.36 per share on revenue of $1.15B. Illumina beat the earnings estimate in 7 of its last 8 reports, moving 10.7% on average across the report.
What is Illumina’s 52-week high and low?
Illumina’s 52-week high is $250.06 and its 52-week low is $88.00; it closed at $239.62 on Sep 18, 2026, +137.6% over the past year.
Is Illumina stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk) and 3 as headwinds (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Illumina the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.